Pharmacokinetics of Delafloxacin in Subjects With and Without Hepatic Impairment

NCT02245243 | Completed Phase 1 DMC

• 1 other identifier: ML-3341-112
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

The purpose of this study is to evaluate the pharmacokinetic profile, safety, and tolerability of a single intravenous (IV) dose of delafloxacin in normal healthy subjects and subjects with mild, moderate, or severe hepatic impairment.

Conditions

Hepatic Impairment

Keywords

Hepatic Impairment, single dose, intravenous

Outcome Measures

Primary Outcomes (1)

• Plasma pharmacokinetic parameters: • AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz

  Baseline through 72 hours post-dose

Secondary Outcomes (1)

• Safety endpoints: AEs, clinical laboratory results (serum chemistry, coagulation, hematology, and urinalysis), vital sign measurements, 12-lead ECG measurements, and physical examination findings

  Baseline through 72 hours post-dose

Study Arms (1)

Delafloxacin

EXPERIMENTAL

Single Dose 300 mg IV

Drug: Delafloxacin

Interventions

Delafloxacin DRUG

Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz

Delafloxacin

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Body mass index (BMI) between 18.5 and 40 kg/m2, inclusive.
• Able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
• Hepatically Impaired Subjects Only (Groups A, B, and C):
• Has a clinical diagnosis of cirrhosis and has been classified as having mild (Group A), moderate (Group B), or severe (Group C) hepatic impairment as defined by the Child-Pugh classification system (Section 7.2).
• Healthy Subjects Only (Group D):
• Must be in good health as determined by the investigator based on medical history, clinical laboratory results, vital sign measurements, 12 lead electrocardiogram \[ECG\] results, and physical examination findings

You may not qualify if:

• All Subjects (Groups A through D):
• Has a clinically significant abnormality in past medical history or at the screening physical examination (excluding hepatic impairment and other related stable medical conditions within the hepatically impaired population of subjects) that in the investigator's or sponsor's opinion may place the subject at risk or interfere with outcome variables of the study. This includes, but is not limited to, history or current cardiac, renal, neurologic, gastrointestinal, respiratory, hematologic, or immunologic disease.
• History or presence of an abnormal ECG that, in the investigator's opinion, is clinically significant and would preclude study participation.
• Has any surgical or medical condition (active or chronic) that may interfere with drug absorption, distribution, metabolism, or excretion of the study drug, or any other condition that may place the subject at risk (history of cholecystectomy is allowed).
• Has a functioning liver transplant
• Has a history of drug and/or alcohol abuse within 6 months before Screening
• Has a history of or current clinically significant mental disorder or an antagonistic personality that compromises the validity of the informed consent.
• Has donated blood or plasma within 30 days before dosing, or has lost more than 1200 mL of blood within 4 months before the first dose of study drug.
• Has a history of AIDS or subject has positive results for HIV at Screening.
• Hepatically Impaired Subjects Only (Groups A, B, and C):
• Has had clinical exacerbation of liver disease within 14 days before study drug administration (eg, abdominal pain, ascites, nausea, vomiting, anorexia, fever, or worsening of laboratory results related to hepatic function).
• Has evidence of acute viral hepatitis within 1 month before Day -1, has clinically demonstrable massive tense ascites, has evidence of severe or acute renal failure, has active stage 3 or stage 4 encephalopathy.
• Healthy Subjects Only (Group D):
• Has a positive test result for hepatitis B surface antigen or hepatitis C virus antibody.

Sponsors & Collaborators

• Melinta Therapeutics, Inc.: lead

Study Sites (2)

Melinta 112 Study Site

Miami, Florida, 33136, United States

Location

Melinta 112 Study Site

Orlando, Florida, 32809, United States

Location

Related Publications (1)

• Hoover R, Marbury TC, Preston RA, Quintas M, Lawrence LE, Paulson SK, Luke DR, Cammarata SK. Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. J Clin Pharmacol. 2017 Mar;57(3):328-335. doi: 10.1002/jcph.817. Epub 2016 Oct 14.

  PMID: 27570245 DERIVED

MeSH Terms

Interventions

delafloxacin

Study Officials

• Sue K Cammarata, MD

  CMO, MelintaTtherapeutics, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 17, 2014
• First Posted: September 19, 2014
• Study Start: September 1, 2014
• Primary Completion: February 1, 2015
• Study Completion: February 1, 2015
• Last Updated: April 30, 2015

Record last verified: 2015-04

Locations

US (2)